Anticipated Near-Term Milestones
- Completion of feasibility studies for the hydrogel depot delivering anti-VEGF drugs in collaboration with several pharmaceutical partners, expected in the first quarter of 2015.
- Phase 3 results of OTX-DP for the treatment of post-operative ocular inflammation and pain, expected in the first quarter of 2015, and assuming favorable results the submission of an NDA to the
FDA , expected in the second quarter of 2015.
